Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 345.00p 330.00p 360.00p 345.00p 345.00p 345.00p 15,462 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 74.6 15.2 17.6 19.6 233

Eco Animal Health Share Discussion Threads

Showing 601 to 624 of 1075 messages
Chat Pages: Latest  31  30  29  28  27  26  25  24  23  22  21  20  Older
DateSubjectAuthorDiscuss
25/4/2016
13:55
Breakout continues....
audigger
22/4/2016
10:45
It was 2 days for meat of offal. This may have changed but I haven't been able to find confirmation of this
audigger
22/4/2016
09:44
I've not double checked, Au, but I thought they had got a zero day withholding period for pigs.
aimingupward2
22/4/2016
09:28
When it comes to approval of new uses in the EU, nothing is inevitable. It takes a lot of effort in terms of data generation and discussions with regulators, often over a number of years, to secure such approvals. It's good that they have secured a zero day withholding period. I don't think they have this yet for other uses in the E U such as pigs, however they will almost certainly be working on it.
audigger
22/4/2016
09:15
This morning's rns is really encouraging further confirmation of EAH's potential. I just wonder, though, how the ambition to make the company a major force in the international market for veterinary products squares with what has tended to be the view that it will be bought out. They're not necessarily alternatives, of course, but the more emphasis is given to the former, the more delayed would be the latter. Either way, it's a comfortingly reliable investment to hold on to. I would add if any weakness occurs over the summer.
aimingupward2
22/4/2016
08:44
surely the wider used aivlosin is becoming, makes things inevitable here........in my opinion anyway
smelleroo
22/4/2016
07:18
Eggcellent news (sorry!). As I posted on March 31st use in egg laying hens was a rather big gap in the EAH offer so this is a really significant step forward. I don't know the numbers but there must be potential to sell significant volumes of product at a decent margin in to this market segment. All bodes well for further step changes in the bottom line
audigger
22/4/2016
07:10
good news continues to go the right way
smelleroo
19/4/2016
09:12
Would be nice to get a trading above expectations RNS! I wonder if they make think about moving away from AIM and listing on the main index? Involves lots of admin costs I know but would certainly increase visibility. Final results in July will be the next expected milestone and hopefully they will be hugely impressive helped further by the relatively weak pound. I wonder where they got to with exploring the anti-viral potential of Aivlosin.....I think they had some research ongoing at Cambridge Uni but this seems to have never come to fruition.
audigger
18/4/2016
19:54
I spoke to my broker who has seen the note. He was saying that there was seem decent emphasis in the note about the attractiveness to a third party primarily in relation to aivlosin. They seem very upbeat about trading too! I haven't seen but broker was saying peel hunt seem pretty upbeat about eco
smelleroo
14/4/2016
19:24
Anyone else heard that the broker wrote a note on Eco suggesting could be attractive to an acquirer?
smelleroo
07/4/2016
15:47
nice to see some volume today
smelleroo
01/4/2016
21:17
I have held a position for over a decade! Have waited a long time for PL to build this company. To give him credit, he has done that! This is v good medicine which will attract buyers as barriers to entry are so big. No one is going to go through what Eco has done when they can just buy Eco. Worth pointing out the PL isn't getting any younger but there are big synergies here for a trade buyer. I am upbeat for next set of results as I would expect good overseas business growth in China and us as well benefits of strong dollar. Peel hunt, the brokers, have this as one of their sticks for 2016. Good call so far! Will it see out the remainder of 2016, that has to be a question on many people's minds
smelleroo
01/4/2016
20:21
I've definitely not re-branded! My impression with this company is that if they were sold to a global company margins would be much higher and central costs virtually disappear. Think this does genuinely have the possibility of doubling or tripling from here - the business could be worth a lot more in the right hands. Of course, the sales momentum needs to be maintained. Bought mine at 93p so definitely doing very well. Shame I didn't buy more than I did back in 2008!
topvest
01/4/2016
16:45
Too many times I've seen a paper profit evaporate in to a paper loss.....I thinkin Soros said his greatest regret was closing winning positions too soon. He did ok though! I'm going to hold these until interims....when I expect only good news as the bottom line continues to grow with the US business starting to fully kick in. Wish I'd sold my RBS shares at 400.....
audigger
01/4/2016
13:30
dont you run your winners..........look at buffett. eah has big barriers to entry
smelleroo
01/4/2016
10:54
AuDigger - yes that's my view too.
aimingupward2
01/4/2016
10:02
I'm in two minds about whether to hold in the anticipation the PL sells the company as he executes his exit plan or whether to sell now and take a handsome profit. I bought mine at prices ranging from 140-220 so am sitting on a good return. However, as revenue/profit continues to grow the divi should continue to increase so these are OK from an income perspective and any take out is likely to be at a significant premium to the current share price ....400-500 is my guess. On balance I think I'll hold. What ever happened to ITinvest? Or is topvest a re-branded version of IT?....I say that based on on similarity of the name.
audigger
01/4/2016
09:01
topvest, when you say "our patience will be rewarded", what are your expectations? The share price is already on a pretty high p.e. ratio, so might it not be more a case of future earnings catching up with the share price rather than the other way round? I do appreciate, though, that a buy-out might well be at a higher rating as a company with it's own sales force(s) would make higher margins than EAH is currently able to do using sales agents - is that your main driver of hope?
aimingupward2
31/3/2016
20:09
And so only two posts today! This isn't on anyone's radar. This business is in great shape and growing well in different geographies. Also the business benefits from strong US dollar. We surely have to be catching the eye of some people or should that be companies ;)
smelleroo
31/3/2016
20:03
All shaping up nicely for ECO. Our patience will be rewarded min my view. Just a matter of waiting for value to crystallise.
topvest
31/3/2016
08:45
Nice to see the share price jump on this news. Was doing some digging on the technical profile of Aivlosin and I was surprised to see that it isn't approved for use on egg laying hens in the EU. If they manage to generate the data to support this approval then there will be much more upside to the EU business in addition to the huge opportunity in the US. It was interesting to see that FDA allowed a zero day withholding period as Eco tried to get this in Europe but it wasn't approved. Theoretically the FDA allowing this jay give Eco some leverage to re-state their case for having the same in Europe
audigger
31/3/2016
07:19
bullish update....... Peter Lawrence, Chairman of ECO commented “We are delighted to receive this marketing authorisation in the United States. This key milestone follows many years of investment in product development and regulatory activity in North America. The USA represents more than one third of the world market for our products and this breakthrough will benefit our future profitable growth. It underlines ECO’s continued commitment to being a major force in the international market for veterinary pharmaceutical products”.
smelleroo
25/2/2016
13:50
Pill-Popping Pigs Put Humans at Risk of Disease: Editorial 2016-02-25 13:00:34.313 GMT By The Editors (Bloomberg View) -- If humans take too many antibiotics -- and they do -- then the animals they eat take even more. Learning more about how and why farmers use so many drugs is crucial to arresting the speed at which bacteria are developing immunity to them. This immunity is a major global threat to public health. Antibiotic-resistant infections kill 23,000 people each year in the U.S. alone and cost $55 billion in medical treatment and lost work days. So President Barack Obama’s 2017 budget contains money to pay for better data on the scope of antibiotic use in farm animals. Congress, which has dropped such funding in the past, needs to see that this time it gets through. The use of antibiotics in agriculture is on the rise: Since 2009, when the Food and Drug Administration began measuring antibiotics given to food animals, use has risen 22 percent. The drugs are typically delivered in feed and water to prevent disease in cattle, pigs, chickens and turkeys and to help them grow. As bacteria that infect farm animals become immune to the drugs, they threaten to jump off the farm and into the human population, as has happened with avian flu in Asia. Unfortunately, that increase, derived from the drug makers’ sales figures, is essentially all that’s known about the scope of antibiotic use in food animals. Farms supply no usage statistics, so it’s impossible to know how much of each drug is given to each type of animal, and at what ages; whether the drugs have been prescribed for an actual illness, as a prophylactic against common diseases, or simply to increase growth; and how exactly they’re administered. Obama’s budget proposes to increase USDA spending to $61 million to help collect the missing data. The bad news is that in last year’s budget proposal, the president allocated $77 million for such research, but when the final omnibus budget deal materialized at the end of 2015, that money was nowhere to be found. Public health experts fear the disappearing act will be repeated once Congress, a strong ally of farm and pharmaceutical interests, makes final appropriations. This would be doubly unfortunate, as a better data- collection regime could build on improved Food and Drug Administration regulations that, by the end of this year, will end the agricultural use of antibiotics for growth enhancement alone, require stronger oversight of diseased animals by veterinarians, and improve record-keeping. Some of biggest producers and retailers in the U.S., including Perdue and Wal-Mart, have demonstrated a real desire to reduce their dependence on antibiotics. They could work with government scientists in a public-private effort to help growers change their animals’ diets and living conditions so as to raise healthy and robust livestock with fewer drugs. A similar compromise had great success in Denmark, a major pork exporter. To create a better system, however, we first need far more detailed information about how antibiotics are being used on the farm.
smelleroo
Chat Pages: Latest  31  30  29  28  27  26  25  24  23  22  21  20  Older
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191015 14:16:06